Clinical Trial

QLS5212 for Participants With Advanced Solid Tumors

Name: QLS5212 for Participants With Advanced Solid Tumors — clinical trial record (NCT07467629)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase 1, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered QLS5212 in participants with unresectable locally, advanced or metastatic cancer.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-20

Trial Details

NCT Number	NCT07467629
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Solid Tumor Cancer
Enrollment	100 participants
Start Date	2026-05-11
Primary Completion	2027-11-05 (estimated)
Study Completion	2028-04-05 (estimated)
Updated on ClinicalTrials.gov	2026-05-19